{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:16:19Z","timestamp":1790644579965,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","award":["1I01BX001018"],"award-info":[{"award-number":["1I01BX001018"]}],"id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007165","name":"University of Missouri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AR070620"],"award-info":[{"award-number":["R21AR070620"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56DK084045"],"award-info":[{"award-number":["R56DK084045"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.bone.2020.115254","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T11:46:08Z","timestamp":1579952768000},"page":"115254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5432-3759","authenticated-orcid":false,"given":"Kathryn M.","family":"Thrailkill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Clay","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasidhar","family":"Uppuganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn S.","family":"Pennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Fowlkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry S.","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2020.115254_bb0005","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.bone.2020.115254_bb0010","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"issue":"22","key":"10.1016\/j.bone.2020.115254_bb0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bone.2020.115254_bb0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2020.115254_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007165","article-title":"Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis","volume":"7","author":"Zhang","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.bone.2020.115254_bb0030","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.bone.2020.115254_bb0035","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.bone.2020.115254_bb0040","first-page":"315","article-title":"Glycemic effects of Sglt-2 inhibitor canagliflozin in type 1 diabetes patients using the Dexcom G4 Platinum Cgm. Endocrine practice: official journal of the American College of Endocrinology and the","volume":"22","author":"Argento","year":"2016","journal-title":"American Association of Clinical Endocrinologists"},{"issue":"12","key":"10.1016\/j.bone.2020.115254_bb0045","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.bone.2020.115254_bb0050","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.bone.2020.115254_bb0055","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.bone.2020.115254_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"1\u20132","key":"10.1016\/j.bone.2020.115254_bb0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0009-8981(99)00040-6","article-title":"Sex difference in the relationship of calcium and magnesium excretion to glycaemic control in type 1 diabetes mellitus","volume":"283","author":"Brown","year":"1999","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"3","key":"10.1016\/j.bone.2020.115254_bb0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/157339910791162970","article-title":"Bone disease in diabetes","volume":"6","author":"Isidro","year":"2010","journal-title":"Curr. Diabetes Rev."},{"issue":"2","key":"10.1016\/j.bone.2020.115254_bb0075","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1542\/peds.78.2.298","article-title":"Hypercalciuria, hyperphosphaturia, and growth retardation in children with diabetes mellitus","volume":"78","author":"Malone","year":"1986","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.bone.2020.115254_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2020.115254_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.bone.2020.115254_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1681\/ASN.2010080888","article-title":"The sweet pee model for Sglt2 mutation","volume":"22","author":"Ly","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.bone.2020.115254_bb0095","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.bone.2020.115254_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bonr.2017.07.001","article-title":"Preserving and restoring bone with continuous insulin infusion therapy in a mouse model of type 1 diabetes","volume":"7","author":"Nyman","year":"2017","journal-title":"Bone Reports"},{"key":"10.1016\/j.bone.2020.115254_bb0105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2018.02.005","article-title":"Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age","volume":"110","author":"Creecy","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115254_bb0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","article-title":"SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice","volume":"82","author":"Thrailkill","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115254_bb0115","series-title":"The Handbook of Research Synthesis","first-page":"231","article-title":"Parametric measures of effect size","author":"Rosenthal","year":"1994"},{"issue":"4","key":"10.1016\/j.bone.2020.115254_bb0120","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav. Res. Methods"},{"issue":"1","key":"10.1016\/j.bone.2020.115254_bb0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1681\/ASN.2010091006","article-title":"Risks and benefits of sweet pee","volume":"22","author":"Lang","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.bone.2020.115254_bb0130","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3168\/jds.S0022-0302(05)72953-2","article-title":"Cloning and expression of bovine sodium\/glucose cotransporter SGLT2","volume":"88","author":"Zhao","year":"2005","journal-title":"J. Dairy Sci."},{"issue":"8","key":"10.1016\/j.bone.2020.115254_bb0135","doi-asserted-by":"crossref","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","article-title":"Expression of Na+\u2212D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences","volume":"302","author":"Sabolic","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"1_supplement","key":"10.1016\/j.bone.2020.115254_bb0140","first-page":"1099.5","article-title":"No extrarenal expression of SGLT2 and sex differences in renal expression","volume":"26","author":"Rose","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.bone.2020.115254_bb0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bone.2016.10.026","article-title":"The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes","volume":"94","author":"Thrailkill","year":"2017","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2020.115254_bb0150","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch."},{"issue":"4","key":"10.1016\/j.bone.2020.115254_bb0155","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jdi.12625","article-title":"Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis","volume":"8","author":"Cai","year":"2017","journal-title":"J. Diabetes Investig"},{"issue":"2","key":"10.1016\/j.bone.2020.115254_bb0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0021-9290(95)00048-8","article-title":"The effects of ageing and changes in mineral content in degrading the toughness of human femora","volume":"29","author":"Currey","year":"1996","journal-title":"J. Biomech."},{"issue":"1121","key":"10.1016\/j.bone.2020.115254_bb0165","first-page":"509","article-title":"Effects of differences in mineralization on the mechanical properties of bone","volume":"304","author":"Currey","year":"1984","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"issue":"3","key":"10.1016\/j.bone.2020.115254_bb0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/eje.0.1490209","article-title":"Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis","volume":"149","author":"Giannini","year":"2003","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2020.115254_bb0175","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.bone.2010.12.016","article-title":"Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone","volume":"48","author":"Nyman","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2020.115254_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154700","article-title":"Advanced glycation endproducts and bone material properties in type 1 diabetic mice","volume":"11","author":"Rubin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2020.115254_bb0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jmbbm.2015.08.012","article-title":"A direct role of collagen glycation in bone fracture","volume":"52","author":"Poundarik","year":"2015","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"10.1016\/j.bone.2020.115254_bb0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bone.2013.11.015","article-title":"Nanoscale changes in collagen are reflected in physical and mechanical properties of bone at the microscale in diabetic rats","volume":"60","author":"Hammond","year":"2014","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2020.115254_bb0195","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jbiomech.2005.01.012","article-title":"The influence of water removal on the strength and toughness of cortical bone","volume":"39","author":"Nyman","year":"2006","journal-title":"J. Biomech."},{"issue":"1","key":"10.1016\/j.bone.2020.115254_bb0200","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1038\/s41598-019-43542-7","article-title":"Assessing matrix quality by Raman spectroscopy helps predict fracture toughness of human cortical bone","volume":"9","author":"Unal","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bone.2020.115254_bb0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2020.115254_bb0210","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.bone.2020.115254_bb0215","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/dom.13176","article-title":"Initiation of dapagliflozin and treatment-emergent fractures","volume":"20","author":"Toulis","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"10.1016\/j.bone.2020.115254_bb0220","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.bone.2020.115254_bb0225","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.clinthera.2016.03.031","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Kohler","year":"2016","journal-title":"Clin. Ther."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822030034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822030034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:40:35Z","timestamp":1762659635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822030034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":45,"alternative-id":["S875632822030034X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115254","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115254"}}